AlphaStocks
5.0
Consider Buy

Amgen Inc (AMGN)

As of Sep 19, 2026, Amgen Inc (AMGN) scores 5.0/10 on AlphaStocks' five-model composite, #113 of 168 Health Care stocks. At $386, AMGN trades 15% above its model fair value of $336.

Health Care / Biotechnology

S&P 500

$385.61

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 19, 2026

#113out of 168 in Health Care

Is AMGEN INC a Good Investment in 2026?

AMGEN INC (AMGN) scores 5.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates AMGEN INC as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. AMGEN INC currently trades 15% above its estimated fair value of $336. AMGEN INC ranks #113 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E27.1ROE22.7Market Cap210BDiv Yield2.6

Estimated Fair Value

$336.2015% above

Trading above estimated fair value. Rapid eps growth (88%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 4.2 · Stalwart

Greenblatt

Neutral

Earnings yield 3.7% · ROC 79%

Frequently Asked Questions

Is AMGEN INC (AMGN) a good investment?
As of Sep 19, 2026, Amgen Inc (AMGN) scores 5.0/10 on AlphaStocks' five-model composite, #113 of 168 Health Care stocks. At $386, AMGN trades 15% above its model fair value of $336. That score is below average, suggesting caution.
What is AMGEN INC's Piotroski F-Score?
AMGEN INC's Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is AMGN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $336, AMGN appears overvalued. The stock currently trades 15% above its estimated fair value. Trading above estimated fair value. Rapid eps growth (88%) partially justifies the premium.
How does AMGN compare to other Health Care stocks?
AMGEN INC ranks #113 out of 168 stocks in the Health Care sector, placing it in the top 67% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about AMGN?
AlphaStocks evaluates AMGN using five proven investment models. Piotroski: Strong; Buffett: Neutral; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 5.0/10.

Similar Stocks

ABBVINCYHRMY

Compare AMGN with

ABBV vs AMGNAMGN vs INCYAMGN vs HRMY

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer